Anti–Helicobacter pylori Treatment in Patients With Gastric Cancer After Radical Gastrectomy
Authors: Zhao Zhoukai , Zhang Ruopeng , Chen Guoming , Nie Man , Zhang Feiyang , Chen Xiaojiang , Lin Jun , Chen Zewei , Lin Feizhi , Wei Chengzhi , Zheng Ziqi , Ruan Shenghang , Huang Bowen , Chen Yingbo , Nie Runcong 
Published: March 2024

ImportanceWhether anti–Helicobacter pylori treatment can provide survival benefits for patients with gastric cancer who are diagnosed with H pylori infection is an area with limited research.ObjectiveTo explore the potential survival benefits of anti–H pylori treatment after radical gastrectomy in patients with gastric cancer and presurgical confirmation of H pylori infection.Design, Setting, and ParticipantsThis retrospective cohort study was conducted using data from patients with gastric cancer treated between January 1, 2010, and December 31, 2018, and followed up for outcome ascertainment until May 19, 2021. Propensity score matching was performed in patients treated with or without anti–H pylori treatment. This study involved a single institute in a comprehensive cancer treatment and research center located in Guangzhou, Guangdong Province, China. The study included patients with gastric or esophagogastric junction adenocarcinoma who underwent curative gastrectomy with D2 lymphadenectomy and tested positive for H pylori infection. Data were analyzed from March to June 2023.ExposureAnti–H pylori treatment, which primarily includes triple therapy regimens consisting of amoxicillin, clarithromycin, and omeprazole for 14 days.Main Outcomes and MeasuresClinical outcomes, including overall survival (OS) and disease-free survival (DFS), were analyzed by Kaplan-Meier method, log-rank test, and Cox proportional hazards regression model. Subgroup analysis based on crucial clinical information was also conducted.ResultsAll 1293 patients (median [IQR] age, 59 [50-65] years; 860 [66.5%] male) were divided into 2 groups, with 125 patients in the anti–H pylori treatment group and 1168 patients in the non–anti–H pylori treatment group based on whether they received anti–H pylori treatment during the perioperative period and the follow-up. Survival analysis showed that the 5-year OS rates were 94.1% (95% CI, 89.3%-99.2%) in the anti–H pylori group and 73.8% (95% CI, 70.7%-77.0%) in the non–anti–H pylori group, and the hazard ratio (HR) of these 2 groups was 0.33 (95% CI, 0.18-0.60; P &amp;lt; .001). The survival benefit remained after propensity score matching (HR, 0.50; 95% CI, 0.26-0.99; P = .048). Multivariable analysis for OS and DFS further showed the survival benefit of anti–H pylori treatment, with HRs of 0.38 (95% CI, 0.17-0.87; P = .02) and 0.48 (95% CI, 0.28-0.83; P = .008), respectively. Among patients with TNM stage II/III disease who received adjuvant chemotherapy, anti–H pylori treatment was associated with survival benefits (OS: HR, 0.49; 95% CI, 0.24-0.99; P = .046), whereas among those who did not receive adjuvant chemotherapy, anti–H pylori treatment was not associated with survival benefits (OS: HR, 0.29; 95% CI, 0.04-2.08; P = .22).Conclusions and RelevanceThis cohort study indicates that anti–H pylori treatment may be associated with improved survival in patients with gastric cancer who have H pylori infections. The study reinforces the importance of including H pylori screening and treatment in the surgical treatment of these patients.